Pilot Study Assessing the Safety, Tolerability, Compliance and Efficacy of Twice Daily Dosed Pylera [tripotassium dicitrato bismuthate/tetracycline/metronidazole] Plus Omeprazole as a First Line Treatment of Helicobacter Pylori Infection
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Omeprazole; Tripotassium dicitrato bismuthate/tetracycline/metronidazole
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- Sponsors Adare Pharmaceuticals
- 17 Dec 2008 Status changed from not yet recruiting to withdrawn prior to recruitment.
- 30 Jul 2008 New trial record.